Avanir's Zenvia passes Phase III pseudobulbar affect trial
This article was originally published in Scrip
Executive Summary
Avanir's Zenvia (dextromethorphan/quinidine sulfate) significantly reduced episode rates of pseudobulbar affect (PBA) in the Phase III STAR trial, top-line data show. The company's shares closed up by 30% at $2.84 on Nasdaq on August 11th.